文献速递肝病

2004至2018年美国肝病成人医疗可负担性及其对死亡率的影响

Healthcare affordability and effects on mortality among adults with liver disease from 2004 to 2018 in the United States.
PubMed 文献 · J Hepatol · 2023-03-30

基于2004至2018年美国国家健康访谈调查与死亡索引链接数据,分析肝病成人医疗可负担性与可及性问题及其与全因死亡率的关联。肝病成人报告医疗服务和药物可负担性问题的年龄调整比例分别为29.9%和15.5%,高于无肝病成人(18.1%和8.2%)。肝病成人中经济困难与全因死亡率升高相关(aHR 1.24,95% CI 1.01-1.53)。

要点

  • 肝病成人医疗服务可负担性问题比例为29.9%,高于无肝病成人的18.1%。
  • 肝病成人药物可负担性问题比例为15.5%,高于无肝病成人的8.2%。
  • 肝病成人中经济困难与全因死亡率升高相关(aHR 1.24,95% CI 1.01-1.53)。

核心结论

  • 肝病成人比无肝病成人和有癌症史的成人面临更大的经济困难。
  • 经济困难与肝病成人全因死亡率升高相关(aHR 1.24,95% CI 1.01-1.53)。
  • 作者认为应优先对该人群采取改善医疗可负担性的干预措施。

研究设计与样本

  • 使用2004至2018年美国国家健康访谈调查数据,按肝病及其他慢性病报告对成人分类,并链接国家死亡索引的死亡率数据。
  • 肝病成人n=19,407,无肝病成人n=996,352,有癌症史成人n=37,225,有肺气肿成人n=7,937,有冠状动脉疾病成人n=21,510。
  • 采用多变量逻辑回归评估肝病与经济困难的关联,采用Cox回归评估经济困难与全因死亡率的关联。

主要发现

  • 报告医疗服务可负担性问题的年龄调整比例:肝病成人29.9%(95% CI 29.7-30.1%)vs 无肝病成人18.1%(95% CI 18.0-18.3%)、癌症史成人26.5%(95% CI 26.3-26.7%)、肺气肿成人42.2%(95% CI 42.1-42.4%)、冠状动脉疾病成人31.6%(95% CI 31.5-31.8%)。
  • 报告药物可负担性问题的年龄调整比例:肝病成人15.5%(95% CI 15.4-15.6%)vs 无肝病成人8.2%(95% CI 8.1-8.3%)、癌症史成人14.8%(95% CI 14.7-14.9%)、肺气肿成人26.1%(95% CI 26.0-26.2%)、冠状动脉疾病成人20.6%(95% CI 20.5-20.7%)。
  • 多变量分析中,肝病(对比无肝病、癌症史、肺气肿、冠状动脉疾病)与无法负担医疗服务相关:aOR分别为1.84(95% CI 1.77-1.92)、1.32(95% CI 1.25-1.40)、0.91(95% CI 0.84-0.98)、1.11(95% CI 1.04-1.19)。
  • 多变量分析中,肝病(对比无肝病、癌症史、肺气肿、冠状动脉疾病)与无法负担药物相关:aOR分别为1.92(95% CI 1.82-2.03)、1.24(95% CI 1.14-1.33)、0.81(95% CI 0.74-0.90)、0.94(95% CI 0.86-1.02)。
  • 肝病成人中,经济困难(对比无经济困难)与全因死亡率升高相关(aHR 1.24,95% CI 1.01-1.53)。

临床怎么用

  • 作者认为应优先对肝病成人采取改善医疗可负担性的干预措施。
  • 作者认为本研究为医疗提供者和政策制定者优先改善肝病成人医疗可负担性提供了动力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Liver disease is associated with substantial morbidity and mortality, likely incurring financial distress (i.e. healthcare affordability and accessibility issues), although long-term national-level data are limited. METHODS: Using the National Health Interview Survey from 2004 to 2018, we categorised adults based on report of liver disease and other chronic conditions linked to mortality data from the National Death Index. We estimated age-adjusted proportions of adults reporting healthcare affordability and accessibility issues. Multivariable logistic regression and Cox regression were used to assess the association of liver disease with financial distress and financial distress with all-cause mortality, respectively. RESULTS: Among adults with liver disease (n = 19,407) vs. those without liver disease (n = 996,352), those with cancer history (n = 37,225), those with emphysema (n = 7,937), and those with coronary artery disease (n = 21,510), the age-adjusted proportion reporting healthcare affordability issues for medical services was 29.9% (95% CI 29.7-30.1%) vs. 18.1% (95% CI 18.0-18.3%), 26.5% (95% CI 26.3-26.7%), 42.2% (95% CI 42.1-42.4%), and 31.6% (31.5-31.8%), respectively, and for medications: 15.5% (95% CI 15.4-15.6%) vs. 8.2% (95% CI 8.1-8.3%), 14.8% (95% CI 14.7-14.9%), 26.1% (95% CI 26.0-26.2%), and 20.6% (95% CI 20.5-20.7%), respectively. In multivariable analysis, liver disease (vs. without liver disease, vs. cancer history, vs. emphysema, and vs. coronary artery disease) was associated with inability to afford medical services (adjusted odds ratio [aOR] 1.84, 95% CI 1.77-1.92; aOR 1.32, 95% CI 1.25-1.40; aOR 0.91, 95% CI 0.84-0.98; and aOR 1.11, 95% CI 1.04-1.19, respectively) and medications (aOR 1.92, 95% CI 1.82-2.03; aOR 1.24, 95% CI 1.14-1.33; aOR 0.81, 95% CI 0.74-0.90; and aOR 0.94, 95% CI 0.86-1.02, respectively), delays in medical care (aOR 1.77, 95% CI 1.69-1.87; aOR 1.14, 95% CI 1.06-1.22; aOR 0.88, 95% CI 0.79-0.97; and aOR 1.05, 95% CI 0.97-1.14, respectively), and not receiving the needed medical care (aOR 1.86, 95% CI 1.76-1.96; aOR 1.16, 95% CI 1.07-1.26; aOR 0.89, 95% CI 0.80-0.99; aOR 1.06, 95% CI 0.96-1.16, respectively). In multivariable analysis, among adults with liver disease, financial distress (vs. without financial distress) was associated with increased all-cause mortality (aHR 1.24, 95% CI 1.01-1.53). CONCLUSIONS: Adults with liver disease face greater financial distress than adults without liver disease and adults with cancer history. Financial distress is associated with increased risk of all-cause mortality among adults with liver disease. Interventions to improve healthcare affordability should be prioritised in this population. IMPACT AND IMPLICATIONS: Adults with liver disease use many medical services, but long-term national studies regarding the financial repercussions and the effects on mortality for such patients are lacking. This study shows that adults with liver disease are more likely to face issues affording medical services and prescription medication, experience delays in medical care, and needing but not obtaining medical care owing to cost, compared with adults without liver disease, adults with cancer history, are equally likely as adults with coronary artery disease, and less likely than adults with emphysema-patients with liver disease who face these issues are at increased risk of death. This study provides the impetus for medical providers and policymakers to prioritise interventions to improve healthcare affordability for adults with liver disease.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ayyala-Somayajula D, Dodge JL, Farias A, et al. Healthcare affordability and effects on mortality among adults with liver disease from 2004 to 2018 in the United States. J Hepatol. 2023. PMID: 36996942. doi:10.1016/j.jhep.2023.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。